Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxoprubart in ANCA-Associated Vasculitis
NCT06226662Phase 2Not yet recruiting
- Sponsor
- NovelMed Therapeutics
- Start
- Jun 2026
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) comparing NM8074 + SOC with Placebo + SOC (2 arms). Primary endpoint: Proportion of subjects achieving disease response at Day 85. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
ruxoprubart
03
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT06226662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06226662.